Bonnefoi, H. Et Al. 2003. An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer.. European journal of cancer (Oxford, England : 1990) , vol.39 , 1277-83.

Bonnefoi, H., Biganzoli, L., Mauriac, L., Cufer, T., Schaefer, P., Atalay, G., ... Piccart, M.(2003). An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer.. European journal of cancer (Oxford, England : 1990) , vol.39, 1277-83.

Bonnefoi, H Et Al. "An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer.," European journal of cancer (Oxford, England : 1990) , vol.39, 1277-83, 2003

Bonnefoi, H Et Al. "An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer.." European journal of cancer (Oxford, England : 1990) , vol.39, pp.1277-83, 2003

Bonnefoi, H. Et Al. (2003) . "An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer.." European journal of cancer (Oxford, England : 1990) , vol.39, pp.1277-83.

@article{article, author={H Bonnefoi Et Al. }, title={An EORTC phase I study of capecitabine (Xeloda) in combination with fixed doses of cyclophosphamide and epirubicin (cex) as primary treatment for large operable or locally advanced/inflammatory breast cancer.}, journal={European journal of cancer (Oxford, England : 1990)}, year=2003, pages={1277-83} }